If anyone doubted the profile of CLTX, the fact our trial (only the first cohort read-out) is being given two time slots in the SNO this year is a sign of how much anticipation / awareness there is about this CLTX trial in the largest market in the world (the US). I mean for such an early stage study, it is getting airtime at oncology conferences in the US. And it will only grow after this event, and I doubt this will be the last time we see our results appear at a conference ... there are many dotted across the calendar, so where our results coincide with one of these, expect it to be showcased.
You'll have to pay to attend, but for those interested ... link is below.
https://www.soc-neuro-onc.org/WEB/Event_Content/Event_Display.aspx?EventKey=AM2021&WebsiteKey=688765ae-3050-4dcd-a797-4aa4c4eff781Looking forward to getting a look at these abstracts, which are coming a little earlier than I anticipated (I expected December to possibly capture the second cohort too).
But early/mid November for the first cohort analysis at the SNO will be coupled with another presentation on what they've learned about how CLTX binds to the surface of GBM cells. While the analysis on the first cohort will be noteworthy, I am particularly interested in the second presentation as it is likely going to shed some light on how CLTX works, and more importantly help CHM recruit patients which are more likely to respond to CLTX.
Why CLTX binds so well to GBM cells is still not fully understood, so by seeing it work in humans for the first time will be extremely insightful. And rather than a 'trust me, it just works' statement on CLTX ... the more they learn about how exactly CLTX works, the better they can define a responsive patient population that will result in a higher chance of a successful trial.
I suspect the second cohort will not be announced until early 2022, but it just adds to the building newsflow we can expect from CHM in 2022.
(20min delay)